Fuda Cancer Hospital
Ewing's sarcoma treatment cost in China typically runs from $75,000 to $140,000 for complex multimodal care. Essential diagnostics like a complete blood count range from $100 to $100, while primary radiation therapy for sarcomas costs $10,500 to $21,700. Total expenses depend on the treatment stage, surgical technology, and clinic tier. Patients often save 50% to 70% compared to the United States. Top treatment hubs include Guangzhou, Shanghai, and Beijing.
Typical Ewing's Sarcoma Treatment Costs in China
Bookimed Expert Insight: Patients with advanced or late-stage Ewing's sarcoma benefit from multidisciplinary care at JCI-accredited centers. Fuda Cancer Hospital in Guangzhou specializes in minimally invasive alternatives to standard chemotherapy, utilizing technologies like NanoKnife and cryosurgery. For those requiring precision radiation, expert-led teams provide IMRT and VMAT protocols. Choosing centers with high international patient volumes ensures access to coordinated, multi-step regimens at competitive rates.
| China | Turkey | Austria | |
| Sarcoma surgery | from $16,500 | from $10,000 | from $35,000 |
| Radiation therapy for colorectal cancer | from $11,500 | from $7,000 | from $12,000 |
| Radiation Therapy for Sarcomas | from $10,500 | from $3,250 | from $18,000 |
| Complex treatment of Ewing's sarcoma | from $75,000 | from $30,000 | from $55,000 |
| Chemotherapy for breast cancer | from $14,800 | from $1,200 | from $15,000 |
No hidden fees – just official clinic prices. Pay at the clinic for Ewing's sarcoma treatment and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Ewing's sarcoma treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Ewing's sarcoma treatment journey.
Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.
He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.
His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.
The doctor is a renowned expert in minimally invasive cryosurgery for cancer, serving as President and chief surgeon at Fuda Cancer Hospital since 2001. With a focus on oncology and minimally invasive procedures, the doctor has performed nearly 10,000 cryosurgeries and 500 NanoKnife procedures, treating patients aged 4 to 94.
Graduating from The Fourth Military Medical University with a specialty in thoracic and cardiac surgery, the doctor has contributed significantly to the field with over 100 published papers. Recognized with awards for outstanding contributions to cryosurgery, the doctor holds vice-presidential roles in both the Asian and International Societies of Cryosurgery.
Ewing sarcoma treatment in China follows a multimodal protocol of systemic chemotherapy, surgical resection, and radiation therapy. Chinese centers utilize international standards from the Chinese Society of Clinical Oncology. Specific regimens include alternating VDC and IE chemotherapy cycles to target the primary tumor and micrometastases.
Bookimed Expert Insight: While major centers follow international guidelines, JCI-accredited facilities like Fuda Cancer Hospital offer unique minimally invasive alternatives. They utilize technologies like NanoKnife and cryosurgery for advanced cases. This allows for localized tumor destruction in patients who cannot tolerate traditional aggressive surgery or high-dose chemotherapy cycles.
Patient Consensus: Patients emphasize traveling to high-volume metropolitan centers for accurate pathology and molecular testing. They note that starting neoadjuvant chemotherapy quickly is vital given the aggressive nature of this sarcoma.
China offers advanced local therapies for sarcomas. These include cryosurgery, NanoKnife, and carbon ion radiotherapy. Specialized centers utilize High-Intensity Focused Ultrasound (HIFU) for non-invasive treatment. These techniques target complex tumors while preserving healthy tissue and critical structures near the tumor site.
Bookimed Expert Insight: Fuda Cancer Hospital stands out for managing late-stage cases using unique combinations. They integrate cryosurgery with vascular interventional therapy for difficult tumors. This approach is particularly valuable for patients from over 100 countries. It serves those whose tumors are considered unresectable in other regions.
Patient Consensus: Patients value the availability of proton therapy for protecting the spine and pelvis. They emphasize that the best results come from teams combining orthopedic oncology with reconstruction specialists.
Top hospitals in China for Ewing's sarcoma include elite institutions like Fuda Cancer Hospital and Beijing Jishuitan Hospital. Specialized centers focus on limb-sparing operations and advanced radiation. These facilities maintain Joint Commission International (JCI) accreditation. They utilize multidisciplinary teams for coordinated chemotherapy, surgery, and radiotherapy protocols.
Bookimed Expert Insight: Coordination between pediatric and orthopedic departments is the strongest quality signal in Chinese centers. Fuda Cancer Hospital manages over 30,000 international patients by offering over 10 types of minimally invasive therapies. This specialized focus on non-systemic treatments provides options for cases where traditional heavy chemotherapy is difficult.
Patient Consensus: Patients emphasize finding a dedicated orthopedic oncology unit rather than a general hospital. They warn that initial biopsy planning is critical to ensuring limb-sparing surgery remains possible later.
Verify Chinese medical quality by confirming a facility Tier 3A (Sanjia) status. This government ranking represents the highest level of safety and technology. Look for Joint Commission International (JCI) accreditation and doctors with Senior Physician (Zhuren Yishi) titles for complex sarcoma care.
Bookimed Expert Insight: Look beyond general cancer volume to find specialized leaders. Professor Dr. Liu Shi Xin at Xiamen Humanity Hospital holds elite State Council honors. This designation is rarer and more significant than standard hospital rankings for complex Ewing's sarcoma cases.
Patient Consensus: Patients emphasize asking for the team’s specific experience with primary bone sarcomas. They recommend getting a written multidisciplinary plan including chemotherapy and radiation before traveling.
Chinese oncology centers often integrate Traditional Chinese Medicine (TCM) with Western protocols. Integrated therapies focus on managing side effects. JCI-accredited facilities like Fuda Cancer Hospital use complementary techniques. These support recovery during bone resection and chemotherapy. Always coordinate with your specialist oncology team first.
Bookimed Expert Insight: Top Chinese oncology centers often focus on biological synergy. Fuda Cancer Hospital uses minimally invasive therapies like NanoKnife alongside TCM. This combination aims to manage advanced stages where standard chemo is difficult. Our data shows patients choose China specifically for this integrative multi-technology approach.
Patient Consensus: Patients emphasize using TCM only for comfort and appetite during treatment. They warn that herbs should never replace surgery or radiation for aggressive sarcomas.